Recursion Pharmaceuticals Inc [RXRX] stock is trading at $4.66, up 7.87%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RXRX shares have gain 6.64% over the last week, with a monthly amount drifted -14.34%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on May 22, 2023, and set its price target to $8. On March 16, 2023, Needham initiated with a Buy rating and assigned a price target of $17 on the stock. KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and suggested a price target of $20 on September 16, 2022. BofA Securities downgraded its rating to a Neutral but $10 remained the price target by the analyst firm on April 18, 2022. SVB Leerink downgraded its rating to Mkt Perform for this stock on March 04, 2022, but kept the price target unchanged to $10. In a note dated September 21, 2021, Berenberg initiated an Buy rating and provided a target price of $37 on this stock.
Recursion Pharmaceuticals Inc [RXRX] stock has fluctuated between $3.79 and $12.36 over the past year. Currently, Wall Street analysts expect the stock to reach $8.75 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $4.66 at the most recent close of the market. An investor can expect a potential return of 87.77% based on the average RXRX price forecast.
Analyzing the RXRX fundamentals
Recursion Pharmaceuticals Inc [NASDAQ:RXRX] reported sales of 43.69M for the trailing twelve months, which represents a drop of -80.16%. Gross Profit Margin for this corporation currently stands at -0.04% with Operating Profit Margin at -10.08%, Pretax Profit Margin comes in at -10.07%, and Net Profit Margin reading is -10.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.76 and Total Capital is -0.57. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.44 points at the first support level, and at 4.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.78, and for the 2nd resistance point, it is at 4.89.
Ratios To Look Out For
For context, Recursion Pharmaceuticals Inc’s Current Ratio is 4.60. Further, the Quick Ratio stands at 4.60, while the Cash Ratio is 3.22. Considering the valuation of this stock, the price to sales ratio is 55.60, the price to book ratio is 2.19.
Transactions by insiders
Recent insider trading involved Borgeson Blake, Director, that happened on Dec 02 ’25 when 0.22 million shares were purchased. Chief Executive Officer, Gibson Christopher completed a deal on Nov 19 ’25 to sell 40000.0 shares. Meanwhile, Officer Gibson Christopher bought 40000.0 shares on Nov 19 ’25.
